Tag: myocardial perfusion
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
1. Obeticholic acid, a farnesoid X receptor agonist, prompts fibrosis improvement in patients with non-alcoholic steatohepatitis (NASH)
Evidence Rating Level: 1 (Excellent)
Non-alcoholic steatohepatitis (NASH) is an increasingly common cause of chronic liver disease...